NEW YORK (GenomeWeb) – Almac Diagnostic Services today announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to determine molecular eligibility for enrolling patients in a pivotal Phase 2 portion of a cancer drug clinical trial.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.